Abingdon HealthABDXF 49 Net-Net Working Capital is $0.01 as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 80 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 1249998.75% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Abingdon Health's Net-Net Working Capital for the quarter that ended in Dec. 2025 was $0.01.
The industry rank for Abingdon Health's Net-Net Working Capital or its related term are showing as below:
ABDXF's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 5.695 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Abingdon Health (OTCPK:ABDXF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Abingdon Health Net-Net Working Capital Related Terms
Abingdon Health Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Net-Net Working Capital Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Price-to-Net-Net-Working-Capital vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.01 mean?
Abingdon Health (ABDXF) has a Net-Net Working Capital of $0.01 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Abingdon Health According to the industry distribution chart, Abingdon Health ranks #999999 out of 80 companies in the Medical Diagnostics & Research industry.
Is Abingdon Health's Net-Net Working Capital too high?
Abingdon Health's current Net-Net Working Capital is $0.01. The Medical Diagnostics & Research industry median Net-Net Working Capital is 5.70. Abingdon Health's value of $0.01 is 99.8% below this industry median. Based on the distribution chart, Abingdon Health ranks #999999 out of 80 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Net-Net Working Capital compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #999999 out of 80 companies for Net-Net Working Capital. This places Abingdon Health in the lower half of its industry. The industry median Net-Net Working Capital is 5.70. Abingdon Health's value of $0.01 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Diagnostics & Research company?
The median Net-Net Working Capital among Medical Diagnostics & Research companies is 5.70, based on 80 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Net-Net Working Capital of $0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Abingdon Health For the Medical Diagnostics & Research industry, the median Net-Net Working Capital is 5.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Net-Net Working Capital is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 26.4% below its estimated fair value. The current Net-Net Working Capital is $0.01 and 99.8% below the Medical Diagnostics & Research industry median of 5.70. Abingdon Health's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Net-Net Working Capital is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.15 is trading 26.4% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Modestly Undervalued.
Key valuation signals for ABDXF:
Net-Net Working Capital: $0.01
GF Value™: $0.21 vs. price of $0.15 (26.4% below fair value)
Industry Position: 99.8% below the Medical Diagnostics & Research median (#999999 of 80)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
